drugset / Trial / NCT04296474

Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass

NCT04296474 ↗

Phase 1/2 Completed 34 enrolled Lars Olaf Cardell
RandomizedParallel-groupOpen-labelTreatment

Summary

52 patients that had previously participated in the RDBPC study of intralymphatic immunotherapy (ILIT) with 2 concomitant allergens, birch and grass, with NCT02423707, were eligible for an open follow up 5-6 years after treatment.

Timeline

Start
2018-05-15
Primary completion
2022-06-20
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator ALK Alutard 5-grasses and birch Other / unclassified — Other

Indications